Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus
NCT02254044 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7
Last updated 2014-10-01
Summary
maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
Conditions
- Carcinoma, Squamous Cell
Interventions
- DRUG
-
bivatuzumab mertansine
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-10-31
- Primary Completion
- 2004-11-30
More Related Trials
-
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
NCT04974047 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC
NCT05807542 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
NCT07290010 ·Status: RECRUITING ·Phase: PHASE2
-
Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus
NCT02586753 ·Status: UNKNOWN ·Phase: PHASE2
-
Oncolytic Virus in Esophageal Squamous Cell Carcinoma
NCT07061704 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma
NCT07188103 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
NCT03957590 ·Status: COMPLETED ·Phase: PHASE3
-
Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer
NCT02253602 ·Status: COMPLETED ·Phase: NA
-
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
NCT07154108 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer
NCT04654403 ·Status: UNKNOWN ·Phase: NA
-
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
NCT00003864 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
NCT06468644 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma
NCT02446574 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
NCT06709417 ·Status: RECRUITING ·Phase: PHASE2
-
SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.
NCT05022654 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
NCT06194734 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)
NCT04767295 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma.
NCT07266480 ·Status: RECRUITING ·Phase: PHASE2
-
Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma
NCT02969473 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT04429542 ·Status: RECRUITING ·Phase: PHASE1
-
Avastin and Taxotere for Esophagogastric Cancer
NCT00137813 ·Status: COMPLETED ·Phase: PHASE2
-
Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma
NCT05637268 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
NCT06463834 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma
NCT00816634 ·Status: UNKNOWN ·Phase: PHASE2
-
Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma
NCT04275986 ·Status: UNKNOWN ·Phase: PHASE2